Tianjin Lisheng Pharmaceutical Co Ltd

Tianjin Lisheng Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 4.37, indicating the company can easily cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score is high, supported by a free cash flow of 367,031,760 CNY and a low debt-to-equity ratio of 0.02, suggesting minimal leverage and strong financial flexibility. In terms of profitability, the company's return on equity (ROE) of 8.99% and return on assets (ROA) of 7.45% are in line with industry norms, indicating efficient use of equity and assets to generate profit. The operating margin, calculated as operating income of 469,076,760 CNY on revenue of 1,392,014,300 CNY, is strong, suggesting effective cost control and pricing power. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification may expose the company to regional economic or regulatory risks. The company's total revenue of 1,392,014,300 CNY is derived from its pharmaceutical products and services, with no material revenue from other sources. Looking ahead, the company is expected to maintain a stable growth trajectory, with no significant changes in revenue or earnings expected in the next fiscal year. The company's capital expenditure of -37,459,300 CNY suggests a reduction in investment in new projects or facilities, which may indicate a focus on cost optimization rather than expansion. The company's free cash flow of 367,031,760 CNY provides flexibility for future growth initiatives or shareholder returns. The company's risk profile is moderate, with a low dilution risk and a medium liquidity risk. The risk assessment indicates that the company has a low probability of issuing new shares in the near term, which is supported by the low dilution risk score. However, the company's net cash position is negative after subtracting total debt, which may pose a liquidity risk if cash flow from operations declines. Recent events, including analyst estimates and financial disclosures, indicate that the company is performing in line with expectations. The last actual EPS was 0.73 CNY, and the last actual revenue was 733,084,000 CNY, suggesting that the company is meeting or slightly exceeding analyst forecasts. No recent filings or transcripts have been disclosed that would indicate significant changes in the company's operations or strategy.